Drugs / KQ-2003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06223646 | Jan 2024 → Mar 2026 | plasma cell myeloma | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04714827 | Jan 2021 → Sep 2024 | plasma cell myeloma | Shanxi Province Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KQ-2003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04714827 ↗ |
| Modality | Cell therapy | “KQ-2003 CAR-T cells immunotherapy” NCT04714827 ↗ |
| Route | Intravenous | “will be intravenously infuse” NCT04714827 ↗ |